{
    "xml": "<topic id=\"PHP4780\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/oxytocin\" basename=\"oxytocin\" title=\"OXYTOCIN\">\n<title>OXYTOCIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_644\" namespace=\"/interactions/list-of-drug-interactions/oxytocin\">Oxytocin</xref>\n</p>\n<data name=\"vtmid\">12369008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_528793212\" title=\"Prostaglandins and oxytocics\">Prostaglandins and oxytocics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP66885\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/oxytocin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Induction of labour for medical reasons</p>\n<p outputclass=\"therapeuticIndication\">Stimulation of labour in hypotonic uterine inertia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 0.001&#8211;0.004&#8239;unit/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3&#8211;4 contractions occur every 10 minutes (0.01&#8239;units/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total 5&#8239;units, stop induction attempt (may be repeated next day starting again at 0.001&#8211;0.004&#8239;units/minute).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Caesarean section</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;units immediately after delivery.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of postpartum haemorrhage after delivery of placenta</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;units, can be used instead of oxytocin with ergometrine (<i>Syntometrine</i>\n<sup>\n<tm tmtype=\"reg\"/>\n</sup>).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of postpartum haemorrhage</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;units, repeated if necessary.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of severe cases of postpartum haemorrhage (following intravenous injection)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>40&#8239;units, given in 500&#8239;mL infusion fluid given at a rate sufficient to control uterine atony.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Incomplete, inevitable, or missed miscarriage</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;units, followed by (by intravenous infusion) 0.02&#8211;0.04&#8239;unit/minute if required, the rate of infusion can be faster if necessary.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65850\" outputclass=\"unlicensedUse\" rev=\"1.10\" parent=\"/drugs/oxytocin\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use</p>\n<p>Oxytocin doses in the BNF may differ from those in the product literature.</p>\n<p>Intramuscular injection.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67394\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/oxytocin\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67457\" outputclass=\"contraindications\" rev=\"1.18\" parent=\"/drugs/oxytocin\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Any condition where spontaneous labour inadvisable</ph>; <ph outputclass=\"contraindication\">any condition where vaginal delivery inadvisable</ph>; <ph outputclass=\"contraindication\">avoid intravenous injection during labour</ph>; <ph outputclass=\"contraindication\">avoid prolonged administration in oxytocin-resistant uterine inertia</ph>; <ph outputclass=\"contraindication\">avoid rapid intravenous injection (may transiently reduce blood pressure)</ph>; <ph outputclass=\"contraindication\">fetal distress (discontinue immediately if this occurs)</ph>; <ph outputclass=\"contraindication\">hypertonic uterine contractions (discontinue immediately if this occurs)</ph>; <ph outputclass=\"contraindication\">severe cardiovascular disease</ph>; <ph outputclass=\"contraindication\">severe pre-eclamptic toxaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67556\" outputclass=\"cautions\" rev=\"1.19\" parent=\"/drugs/oxytocin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication)</ph>; <ph outputclass=\"caution\">enhancement of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)</ph>; <ph outputclass=\"caution\">history of lower-uterine segment caesarean section</ph>; <ph outputclass=\"caution\">induction of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)</ph>; <ph outputclass=\"caution\">mild pregnancy-induced cardiac disease</ph>; <ph outputclass=\"caution\">mild pregnancy-induced hypertension</ph>; <ph outputclass=\"caution\">moderate pregnancy-induced cardiac disease</ph>; <ph outputclass=\"caution\">moderate pregnancy-induced hypertension</ph>; <ph outputclass=\"caution\">risk factors for disseminated intravascular coagulation</ph>; <ph outputclass=\"caution\">secondary uterine inertia</ph>; <ph outputclass=\"caution\">women over 35 years</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66810\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/oxytocin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (oxytocin).</p>\n<p>Effects enhanced by concomitant prostaglandins (very careful monitoring of uterine activity).</p>\n<p>Caudal block anaesthesia (may enhance hypertensive effects of sympathomimetic vasopressors).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP66166\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/oxytocin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arrhythmia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylactoid reactions (with dyspnoea, hypotension, or shock)</ph>; <ph outputclass=\"sideEffect\">disseminated intravascular coagulation</ph>; <ph outputclass=\"sideEffect\">hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">uterine hyperstimulation (usually with excessive doses&#8212;may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture)</ph>; <ph outputclass=\"sideEffect\">uterine spasm (may occur at low doses)</ph>; <ph outputclass=\"sideEffect\">water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Avoid rapid intravenous injection (may transiently reduce blood pressure).</p>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsOverdosageInformation\">\n<title>Overdose</title>\n<sectiondiv>\n<p>Placental abruption and amniotic fluid embolism reported on overdose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP65748\" outputclass=\"monitoringRequirements\" parent=\"/drugs/oxytocin\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Careful monitoring of fetal heart rate and uterine motility essential for dose titration.</p>\n<p>Monitor for disseminated intravascular coagulation after parturition.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP67756\" outputclass=\"directionsForAdministration\" rev=\"1.18\" parent=\"/drugs/oxytocin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Syntocinon</i>\n<sup>\n<tm tmtype=\"reg\"/>\n</sup>), give continuously in Glucose 5% <i>or</i> Sodium chloride 0.9%. Preferably given <i>via</i> a variable-speed infusion pump in a concentration appropriate to the pump; if given by drip infusion for <i>induction</i> or <i>enhancement of labour</i>, dilute 5&#8239;units in 500&#8239;mL infusion fluid or for higher doses, 10&#8239;units in 500&#8239;mL; for <i>treatment of postpartum uterine haemorrhage</i> dilute 40&#8239;units in 500&#8239;mL; if high doses given for prolonged period (e.g. for inevitable or missed abortion or for postpartum haemorrhage), use low volume of an electrolyte-containing infusion fluid (not Glucose 5%) given at higher concentration than for induction or enhancement of labour; close attention to patient's fluid and electrolyte status essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4780-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/oxytocin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: solution for infusion, infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74678\" title=\"Solution for injection\" namespace=\"/drugs/oxytocin/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85596\" namespace=\"/drugs/ergometrine-with-oxytocin\" title=\"ERGOMETRINE WITH OXYTOCIN\" count=\"1\" rel=\"backlink\">ERGOMETRINE WITH OXYTOCIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78308\" namespace=\"/treatment-summaries/posterior-pituitary-hormones-and-antagonists\" title=\"Posterior pituitary hormones and antagonists\" count=\"1\" rel=\"backlink\">Posterior pituitary hormones and antagonists</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78629\" namespace=\"/treatment-summaries/obstetrics\" title=\"Obstetrics\" count=\"10\" rel=\"backlink\">Obstetrics</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_644\" namespace=\"/interactions/list-of-drug-interactions/oxytocin\" title=\"Oxytocin\" count=\"1\" rel=\"link\">Oxytocin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74678\" namespace=\"/drugs/oxytocin/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP4780",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/oxytocin",
    "basename": "oxytocin",
    "title": "OXYTOCIN",
    "interactants": [
        {
            "id": "bnf_int_644",
            "label": "Oxytocin"
        }
    ],
    "vtmid": "12369008",
    "drugClassification": [
        "Prostaglandins and oxytocics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Induction of labour for medical reasons",
                        "html": "Induction of labour for medical reasons"
                    },
                    {
                        "textContent": "Stimulation of labour in hypotonic uterine inertia",
                        "html": "Stimulation of labour in hypotonic uterine inertia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 0.001&#8211;0.004 unit/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3&#8211;4 contractions occur every 10 minutes (0.01 units/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total 5 units, stop induction attempt (may be repeated next day starting again at 0.001&#8211;0.004 units/minute).",
                        "html": "<p>Initially 0.001&#8211;0.004&#8239;unit/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3&#8211;4 contractions occur every 10 minutes (0.01&#8239;units/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total 5&#8239;units, stop induction attempt (may be repeated next day starting again at 0.001&#8211;0.004&#8239;units/minute).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Caesarean section",
                        "html": "Caesarean section"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection"
                    ],
                    "textContent": "By slow intravenous injection",
                    "html": "By slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "5 units immediately after delivery.",
                        "html": "<p>5&#8239;units immediately after delivery.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of postpartum haemorrhage after delivery of placenta",
                        "html": "Prevention of postpartum haemorrhage after delivery of placenta"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "5 units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours.",
                        "html": "<p>5&#8239;units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours.</p>"
                    },
                    {
                        "textContent": "10 units, can be used instead of oxytocin with ergometrine (Syntometrine ).",
                        "html": "<p>10&#8239;units, can be used instead of oxytocin with ergometrine (<i>Syntometrine</i> <sup> <tm tmtype=\"reg\"/> </sup>).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of postpartum haemorrhage",
                        "html": "Treatment of postpartum haemorrhage"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection"
                    ],
                    "textContent": "By slow intravenous injection",
                    "html": "By slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "5 units, repeated if necessary.",
                        "html": "<p>5&#8239;units, repeated if necessary.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of severe cases of postpartum haemorrhage (following intravenous injection)",
                        "html": "Treatment of severe cases of postpartum haemorrhage (following intravenous injection)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "40 units, given in 500 mL infusion fluid given at a rate sufficient to control uterine atony.",
                        "html": "<p>40&#8239;units, given in 500&#8239;mL infusion fluid given at a rate sufficient to control uterine atony.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Incomplete, inevitable, or missed miscarriage",
                        "html": "Incomplete, inevitable, or missed miscarriage"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially slow intravenous injection"
                    ],
                    "textContent": "Initially by slow intravenous injection",
                    "html": "Initially by slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "5 units, followed by (by intravenous infusion) 0.02&#8211;0.04 unit/minute if required, the rate of infusion can be faster if necessary.",
                        "html": "<p>5&#8239;units, followed by (by intravenous infusion) 0.02&#8211;0.04&#8239;unit/minute if required, the rate of infusion can be faster if necessary.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With intramuscular use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use",
                    "routes": [
                        "intramuscular"
                    ]
                },
                "textContent": "Oxytocin doses in the BNF may differ from those in the product literature.\n\nIntramuscular injection.",
                "html": "<p>Oxytocin doses in the BNF may differ from those in the product literature.</p><p>Intramuscular injection.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.",
                "html": "<p>Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Any condition where spontaneous labour inadvisable",
                "html": "Any condition where spontaneous labour inadvisable"
            },
            {
                "type": "contraindications",
                "textContent": "any condition where vaginal delivery inadvisable",
                "html": "any condition where vaginal delivery inadvisable"
            },
            {
                "type": "contraindications",
                "textContent": "avoid intravenous injection during labour",
                "html": "avoid intravenous injection during labour"
            },
            {
                "type": "contraindications",
                "textContent": "avoid prolonged administration in oxytocin-resistant uterine inertia",
                "html": "avoid prolonged administration in oxytocin-resistant uterine inertia"
            },
            {
                "type": "contraindications",
                "textContent": "avoid rapid intravenous injection (may transiently reduce blood pressure)",
                "html": "avoid rapid intravenous injection (may transiently reduce blood pressure)"
            },
            {
                "type": "contraindications",
                "textContent": "fetal distress (discontinue immediately if this occurs)",
                "html": "fetal distress (discontinue immediately if this occurs)"
            },
            {
                "type": "contraindications",
                "textContent": "hypertonic uterine contractions (discontinue immediately if this occurs)",
                "html": "hypertonic uterine contractions (discontinue immediately if this occurs)"
            },
            {
                "type": "contraindications",
                "textContent": "severe cardiovascular disease",
                "html": "severe cardiovascular disease"
            },
            {
                "type": "contraindications",
                "textContent": "severe pre-eclamptic toxaemia",
                "html": "severe pre-eclamptic toxaemia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication)",
                "html": "Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication)"
            },
            {
                "type": "cautions",
                "textContent": "enhancement of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)",
                "html": "enhancement of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)"
            },
            {
                "type": "cautions",
                "textContent": "history of lower-uterine segment caesarean section",
                "html": "history of lower-uterine segment caesarean section"
            },
            {
                "type": "cautions",
                "textContent": "induction of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)",
                "html": "induction of labour&#8212;presence of borderline cephalopelvic disproportion (avoid if significant)"
            },
            {
                "type": "cautions",
                "textContent": "mild pregnancy-induced cardiac disease",
                "html": "mild pregnancy-induced cardiac disease"
            },
            {
                "type": "cautions",
                "textContent": "mild pregnancy-induced hypertension",
                "html": "mild pregnancy-induced hypertension"
            },
            {
                "type": "cautions",
                "textContent": "moderate pregnancy-induced cardiac disease",
                "html": "moderate pregnancy-induced cardiac disease"
            },
            {
                "type": "cautions",
                "textContent": "moderate pregnancy-induced hypertension",
                "html": "moderate pregnancy-induced hypertension"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for disseminated intravascular coagulation",
                "html": "risk factors for disseminated intravascular coagulation"
            },
            {
                "type": "cautions",
                "textContent": "secondary uterine inertia",
                "html": "secondary uterine inertia"
            },
            {
                "type": "cautions",
                "textContent": "women over 35 years",
                "html": "women over 35 years"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (oxytocin).\n\nEffects enhanced by concomitant prostaglandins (very careful monitoring of uterine activity).\n\nCaudal block anaesthesia (may enhance hypertensive effects of sympathomimetic vasopressors).",
                "html": "<p>Appendix 1 (oxytocin).</p><p>Effects enhanced by concomitant prostaglandins (very careful monitoring of uterine activity).</p><p>Caudal block anaesthesia (may enhance hypertensive effects of sympathomimetic vasopressors).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Arrhythmia",
                        "html": "Arrhythmia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Anaphylactoid reactions (with dyspnoea, hypotension, or shock)",
                        "html": "Anaphylactoid reactions (with dyspnoea, hypotension, or shock)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "disseminated intravascular coagulation",
                        "html": "disseminated intravascular coagulation",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid",
                        "html": "hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "uterine hyperstimulation (usually with excessive doses&#8212;may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture)",
                        "html": "uterine hyperstimulation (usually with excessive doses&#8212;may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "uterine spasm (may occur at low doses)",
                        "html": "uterine spasm (may occur at low doses)",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid",
                        "html": "water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Avoid rapid intravenous injection (may transiently reduce blood pressure).",
                "html": "<p>Avoid rapid intravenous injection (may transiently reduce blood pressure).</p>"
            }
        ],
        "overdosageInformation": [
            {
                "type": "overdosageInformation",
                "textContent": "Placental abruption and amniotic fluid embolism reported on overdose.",
                "html": "<p>Placental abruption and amniotic fluid embolism reported on overdose.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Careful monitoring of fetal heart rate and uterine motility essential for dose titration.\n\nMonitor for disseminated intravascular coagulation after parturition.",
                "html": "<p>Careful monitoring of fetal heart rate and uterine motility essential for dose titration.</p><p>Monitor for disseminated intravascular coagulation after parturition.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Syntocinon ), give continuously in Glucose 5% or Sodium chloride 0.9%. Preferably given via a variable-speed infusion pump in a concentration appropriate to the pump; if given by drip infusion for induction or enhancement of labour, dilute 5 units in 500 mL infusion fluid or for higher doses, 10 units in 500 mL; for treatment of postpartum uterine haemorrhage dilute 40 units in 500 mL; if high doses given for prolonged period (e.g. for inevitable or missed abortion or for postpartum haemorrhage), use low volume of an electrolyte-containing infusion fluid (not Glucose 5%) given at higher concentration than for induction or enhancement of labour; close attention to patient's fluid and electrolyte status essential.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Syntocinon</i>\n<sup>\n<tm tmtype=\"reg\"/>\n</sup>), give continuously in Glucose 5% <i>or</i> Sodium chloride 0.9%. Preferably given <i>via</i> a variable-speed infusion pump in a concentration appropriate to the pump; if given by drip infusion for <i>induction</i> or <i>enhancement of labour</i>, dilute 5&#8239;units in 500&#8239;mL infusion fluid or for higher doses, 10&#8239;units in 500&#8239;mL; for <i>treatment of postpartum uterine haemorrhage</i> dilute 40&#8239;units in 500&#8239;mL; if high doses given for prolonged period (e.g. for inevitable or missed abortion or for postpartum haemorrhage), use low volume of an electrolyte-containing infusion fluid (not Glucose 5%) given at higher concentration than for induction or enhancement of labour; close attention to patient's fluid and electrolyte status essential.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "solution for infusion",
                "infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74678",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85596",
                "label": "ERGOMETRINE WITH OXYTOCIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78308",
                "label": "Posterior pituitary hormones and antagonists",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78629",
                "label": "Obstetrics",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_644",
                "label": "Oxytocin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74678",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}